Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
1 "Familial pancreatic cancer"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Article
The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome
Marcin R. Lener, Aniruddh Kashyap, Wojciech Kluźniak, Cezary Cybulski, Agnieszka Soluch, Sandra Pietrzak, Tomasz Huzarski, Jacek Gronwald, Jan Lubiński
Cancer Res Treat. 2017;49(2):430-436.   Published online July 28, 2016
DOI: https://doi.org/10.4143/crt.2016.217
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Familial pancreatic cancer describes families with at least two first-degree relatives with pancreatic cancer that do not fulfil the criteria of other inherited tumor syndromes with increased risks of pancreatic cancer. Although much has been learned regarding the aggregation of pancreatic cancer in some families, the genetic basis for this familial aggregation is poorly understood. This study evaluated the prevalence of 10 Polish founder mutations in four genes among individuals from families with diagnosed familial pancreatic cancer syndrome and assessed their possible associationwith the familial pancreatic cancer (FPC) risk in Poland.
Materials and Methods
In this study, 400 FPC individuals and 4,000 control subjects were genotyped for founder mutations in BRCA1 (5382insC, 4153delA, C61G), CHEK2 (1100delC, IVS2+1G>A, del5395, I157T), NBS1 (657del5), and PALB2 (509_510delGA, 172_175delTTGT) genes.
Results
A statistically significant association was observed between the 172_175delTTGT mutation of the PALB2 gene and an increased risk of FPC syndrome (odds ratio [OR], 10.05; p=0.048). In addition, an increased risk of cancer was observed in the FPC family members with a BRCA1 mutation (OR, 6.72; p=0.006). Novel associations were found between the FPC family members with cancer and CHEK2 mutations (OR, 2.26; p=0.008) with a noticeable contribution of the missense variant, I157T of CHEK2 (OR, 2.17; p=0.026).
Conclusion
The founder mutations in the genes, BRCA1, PALB2, and CHEK2, cause a small percentage of familial pancreatic cancer syndrome in the Polish population. Following confirmation in larger studies, these mutations can be added to the panel of genes to be tested in families with a diagnosis of FPC syndrome.

Citations

Citations to this article as recorded by  
  • Guarding against digestive-system cancers: Unveiling the role of Chk2 as a potential therapeutic target
    Yucheng An, Duolun Gao, Yanjie He, Nan Ge, Jintao Guo, Siyu Sun, Caixia Wang, Fan Yang
    Genes & Diseases.2025; 12(1): 101191.     CrossRef
  • CHEK2 germline variants identified in familial nonmedullary thyroid cancer lead to impaired protein structure and function
    Carolina Pires, Inês J. Marques, Mariana Valério, Ana Saramago, Paulo E. Santo, Sandra Santos, Margarida Silva, Margarida M. Moura, João Matos, Teresa Pereira, Rafael Cabrera, Diana Lousa, Valeriano Leite, Tiago M. Bandeiras, João B. Vicente, Branca M. Ca
    Journal of Biological Chemistry.2024; 300(3): 105767.     CrossRef
  • The role of germline BRCA1 & BRCA2 mutations in familial pancreatic cancer: A systematic review and meta-analysis
    Edward Kurnia Setiawan Limijadi, Muflihatul Muniroh, Yan Wisnu Prajoko, Kevin Christian Tjandra, Danendra Rakha Putra Respati, Alvaro Galli
    PLOS ONE.2024; 19(5): e0299276.     CrossRef
  • Germline variant profiling of CHEK2 sequencing variants in breast cancer patients
    Claire McCarthy-Leo, Scott Baughan, Hunter Dlugas, Prisca Abraham, Janice Gibbons, Carolyn Baldwin, Sarah Chung, Gerald L. Feldman, Gregory Dyson, Russell L. Finley, Michael A. Tainsky
    Cancer Genetics.2024; 288-289: 10.     CrossRef
  • Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)
    Helen Hanson, Esteban Astiazaran-Symonds, Laura M. Amendola, Judith Balmaña, William D. Foulkes, Paul James, Susan Klugman, Joanne Ngeow, Rita Schmutzler, Nicoleta Voian, Myra J. Wick, Tuya Pal, Marc Tischkowitz, Douglas R. Stewart
    Genetics in Medicine.2023; 25(10): 100870.     CrossRef
  • Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review
    Antonino Pantaleo, Giovanna Forte, Candida Fasano, Martina Lepore Signorile, Paola Sanese, Katia De Marco, Elisabetta Di Nicola, Marialaura Latrofa, Valentina Grossi, Vittoria Disciglio, Cristiano Simone
    Cancers.2023; 16(1): 56.     CrossRef
  • Germline genetic variability in pancreatic cancer risk and prognosis
    Manuel Gentiluomo, Federico Canzian, Andrea Nicolini, Federica Gemignani, Stefano Landi, Daniele Campa
    Seminars in Cancer Biology.2022; 79: 105.     CrossRef
  • Identification of high-risk germline variants for the development of pancreatic cancer: Common characteristics and potential guidance to screening guidelines
    Cade Bennett, Mike Suguitan, John Abad, Akhil Chawla
    Pancreatology.2022; 22(6): 719.     CrossRef
  • A Genome-First Approach to Estimate Prevalence of Germline Pathogenic Variants and Risk of Pancreatic Cancer in Select Cancer Susceptibility Genes
    Esteban Astiazaran-Symonds, Jung Kim, Jeremy S. Haley, Sun Young Kim, H. Shanker Rao, Regeneron Genetics Center, David J. Carey, Douglas R. Stewart, Alisa M. Goldstein
    Cancers.2022; 14(13): 3257.     CrossRef
  • Current status of inherited pancreatic cancer
    Marek Olakowski, Łukasz Bułdak
    Hereditary Cancer in Clinical Practice.2022;[Epub]     CrossRef
  • Genetic predisposition to male breast cancer in Poland
    Marek Szwiec, Joanna Tomiczek-Szwiec, Wojciech Kluźniak, Dominika Wokołorczyk, Karolina Osowiecka, Robert Sibilski, Małgorzata Wachowiak, Jacek Gronwald, Helena Gronwald, Jan Lubiński, Cezary Cybulski, Steven A. Narod, Tomasz Huzarski
    BMC Cancer.2021;[Epub]     CrossRef
  • Prevalence of Germline Pathogenic Variants in Cancer Predisposing Genes in Czech and Belgian Pancreatic Cancer Patients
    Greet Wieme, Jan Kral, Toon Rosseel, Petra Zemankova, Bram Parton, Michal Vocka, Mattias Van Heetvelde, Petra Kleiblova, Bettina Blaumeiser, Jana Soukupova, Jenneke van den Ende, Petr Nehasil, Sabine Tejpar, Marianna Borecka, Encarna B. Gómez García, Mari
    Cancers.2021; 13(17): 4430.     CrossRef
  • Assembling and Validating Bioinformatic Pipelines for Next-Generation Sequencing Clinical Assays
    Jeffrey A SoRelle, Megan Wachsmann, Brandi L. Cantarel
    Archives of Pathology & Laboratory Medicine.2020; 144(9): 1118.     CrossRef
  • Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer
    Matthew B. Yurgelun, Anu B. Chittenden, Vicente Morales-Oyarvide, Douglas A. Rubinson, Richard F. Dunne, Margaret M. Kozak, Zhi Rong Qian, Marisa W. Welch, Lauren K. Brais, Annacarolina Da Silva, Justin L. Bui, Chen Yuan, Tingting Li, Wanwan Li, Atsuhiro
    Genetics in Medicine.2019; 21(1): 213.     CrossRef
  • Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer
    Akihiro Ohmoto, Shinichi Yachida, Chigusa Morizane
    International Journal of Molecular Sciences.2019; 20(3): 561.     CrossRef
  • Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma
    O. Obazee, L. Archibugi, A. Andriulli, P. Soucek, E. Małecka‐Panas, A. Ivanauskas, T. Johnson, M. Gazouli, T. Pausch, R. T. Lawlor, G. M. Cavestro, A. C. Milanetto, M. Di Leo, C. Pasquali, P. Hegyi, A. Szentesi, C. E. Radu, C. Gheorghe, G. E. Theodoropoul
    International Journal of Cancer.2019; 145(3): 686.     CrossRef
  • Progress report: familial pancreatic cancer
    Ioannis Mintziras, Detlef K. Bartsch
    Familial Cancer.2019; 18(3): 359.     CrossRef
  • Spectrum of APC and MUTYH germ‐line mutations in Russian patients with colorectal malignancies
    G.A. Yanus, T.A. Akhapkina, A.O. Ivantsov, E.V. Preobrazhenskaya, S.N. Aleksakhina, I.V. Bizin, A.P. Sokolenko, N.V. Mitiushkina, E.Sh. Kuligina, E.N. Suspitsin, A.R. Venina, M.M. Holmatov, O.A. Zaitseva, O.S. Yatsuk, D.V. Pashkov, A.M. Belyaev, A.V. Togo
    Clinical Genetics.2018; 93(5): 1015.     CrossRef
  • Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines
    Akihiro Ohmoto, Chigusa Morizane, Emi Kubo, Erina Takai, Hiroko Hosoi, Yasunari Sakamoto, Shunsuke Kondo, Hideki Ueno, Kazuaki Shimada, Shinichi Yachida, Takuji Okusaka
    Journal of Gastroenterology.2018; 53(10): 1159.     CrossRef
  • Germline Variants and Risk for Pancreatic Cancer
    Wei Zhan, Celeste A. Shelton, Phil J. Greer, Randall E. Brand, David C. Whitcomb
    Pancreas.2018; 47(8): 924.     CrossRef
  • 10,419 View
  • 320 Download
  • 21 Web of Science
  • 20 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP